Group 1: Fudan Zhangjiang - Shareholders Yang Zongmeng and Wang Haibo plan to reduce their holdings by a total of up to 1.41% of the company's shares [1] - Yang Zongmeng intends to sell up to 10.36 million shares, representing 1.00% of the total share capital [1] - Wang Haibo plans to sell up to 4.27 million shares, representing 0.41% of the total share capital [1] Group 2: Aisen Co., Ltd. - Shareholders including Ailong Venture Capital and executives plan to reduce their holdings by a total of up to 3.86% of the company's shares [1] - Ailong Venture Capital intends to sell up to 2.644 million shares, representing 3.00% of the total share capital [1] - Other executives plan to sell smaller amounts, with individual reductions ranging from 0.17% to 0.45% of the total share capital [1] Group 3: Youyou Food - Actual controller Zhao Ying plans to reduce his holdings by up to 3% of the company's shares [3] - The planned reduction amounts to up to 12.83 million shares [3] Group 4: Chenfeng Technology - The company plans to sell idle assets, including 6 vehicles and 53 pieces of machinery, for a total estimated sale price of 8.1461 million yuan [5] - Expected disposal gains from the sale are approximately 3.6238 million yuan [5] Group 5: *ST Hengtai - The company will cancel its delisting risk warning and other risk warnings, with the stock name changing from "*ST Hengtai" to "Henglitai" [6] - The stock will be suspended for one day and the price fluctuation limit will change to 10% [6] Group 6: Xinyunda - Shareholder Wuku International Trust plans to reduce its holdings by up to 3% of the company's shares [9] - The planned reduction amounts to up to 5.9823 million shares [9] Group 7: Shaoyang Hydraulic - The company is planning a major asset restructuring, which involves issuing shares and cash to acquire part or all of Chongqing Xincheng Hangrui Technology Co., Ltd. [10] - The stock will be suspended for up to 10 trading days [10] Group 8: Xingwang Yuda - The company announced that part of its bank account funds, totaling 25.9335 million yuan, have been frozen [11] - The frozen amount represents 1.42% of the company's most recent audited net assets [11] Group 9: Tianrong Tianyu - Shareholder Yan Xuewei plans to reduce his holdings by up to 3% of the company's shares [12] - The planned reduction amounts to up to 4.2089 million shares [12] Group 10: Qiming Star - The chairman Wei Bing has resigned due to work adjustments at China Mobile Communications Group [13] Group 11: Aosaikang - The company's subsidiary has received a drug registration certificate for Methotrexate injection, which is considered equivalent to passing consistency evaluation [15][16] Group 12: Xinhau Optoelectronics - The company plans to transfer 100% equity of its wholly-owned subsidiary, Xinguang Energy Technology (Anhui) Co., Ltd. [17] Group 13: ST Baili - The company's controlling shareholder has been applied for bankruptcy liquidation due to inability to repay debts [19]

证监会拟进一步优化证券公司分类评价制度 证监会就《证券公司分类评价规定（修订草案征求意见稿）》公开征求意见。此次修订重点修改完善四 方面内容。包括：突出促进证券公司功能发挥的导向，完善评价框架；适当整合、优化业务发展指标， 引导行业机构聚焦高质量发展，支持中小机构差异化发展、特色化经营等。 跨境支付通上线 全国首笔业务落地深圳 重要的消息有哪些 财政部：1—5月全国一般公共预算收入96623亿元 同比下降0.3% 财政部数据显示，1—5月，全国一般公共预算收入96623亿元，同比下降0.3%。其中，全国税收收入 79156亿元，同比下降1.6%；非税收入17467亿元，同比增长6.2%。分中央和地方看，中央一般公共预 算收入41486亿元，同比下降3%；地方一般公共预算本级收入55137亿元，同比增长1.9%。 6月22日，跨境支付通正式上线，标志着内地与香港快速支付系统已实现互联互通，今后两地居民可实 时办理跨境汇款。当日，全国首笔跨境支付通内地居民南向、港人北向汇款业务落地深圳。业内人士对 智通财经记者表示，跨境支付通上线有助于提升人民币在跨境零售场景中的使用便利度，进一步推动人 民币国际化进程。从技术角 ...

Core Viewpoint - The company has received the drug registration certificate for Methotrexate Injection from the National Medical Products Administration, which is expected to enhance its competitiveness in the oncology market [1] Group 1: Drug Approval and Market Potential - The company's wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for Methotrexate Injection [1] - The active pharmaceutical ingredient for Methotrexate Injection received a marketing application approval notice in May 2025 [1] - Methotrexate Injection can be used alone to treat breast cancer and gestational trophoblastic neoplasia, or in combination with other chemotherapy drugs for osteosarcoma and acute leukemia [1] Group 2: Sales Performance and Future Impact - According to the PDB database, the average annual sales of Methotrexate Injection in sample hospitals over the past five years is approximately 140 million yuan [1] - The market outlook for Methotrexate Injection is broad, indicating significant sales potential [1] - The acquisition of the drug registration certificate will enrich the company's oncology product portfolio and positively impact the company's future operations [1]